Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors
Brief description of study
To evaluate the safety and tolerability of RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors To estimate the MTD and/or RP2DS for RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors
Clinical Study Identifier: s24-00038
ClinicalTrials.gov Identifier: NCT06128551
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
